Pfizer Inc. (NYSE:PFE) announced encouraging top-line data from a phase IIIb study evaluating Genotropin for increasing height in small-for-gestational-age (SGA) children aged between 24 and 30 months. Pfizer Inc. (NYSE:PFE) shares after opening at $32.28 moved to $32.38 on last trade day and at the end of the day closed at $32.10. Company price to sales ratio in past twelve months was calculated as 4.24 and price to cash ratio as 6.75. Pfizer Inc. (NYSE:PFE) showed a positive weekly performance of 0.60%.
HC Wainwright started coverage on shares of Ariad Pharmaceuticals (NASDAQ:ARIA) in a research note issued on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $14.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 82.53% from the company’s current price. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares fell -0.91% in last trading session and ended the day on $7.60. ARIA return on equity ratio is recorded as -98.50% and its return on assets is -65.80%. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) yearly performance is -58.49%.
Bristol-Myers Squibb Co (NYSE:BMY) along with Pfizer Inc. (NYSE:PFE) proudly announced the benefits of Eliquis on March 27. Bristol-Myers Squibb Co (NYSE:BMY) shares moved down -0.63% in last trading session and was closed at $52.33, while trading in range of $51.51 – $52.57. Bristol-Myers Squibb Co (NYSE:BMY) year to date (YTD) performance is -1.54%.
Cowen and Company started coverage on shares of Idera Pharmaceuticals (NASDAQ:IDRA) in a research report released on Monday morning, TheFlyOnTheWall.com reports. The firm issued an outperform rating on the stock. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) weekly performance is -40.12%. On last trading day company shares ended up $3.88. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) distance from 50-day simple moving average (SMA50) is -24.14%. Analysts mean target price for the company is $7.00.
Leave a Reply